Merck Serono announced that the FDA has approved EMD Serono‘s GONAL-f RFF Redi-ject (recombinant follitropin alfa) injection, a disposable prefilled drug injector pen indicated for the subcutaneous ...

Geneva, Switzerland and Rockland, MA, May 27, 2004 -- Serono, Inc., the US affiliate of Serono (virt-x: SEO and NYSE: SRA), announced today that the United States Food and Drug Administration (FDA) ...

GONAL-f (follitropin alfa injection) is a recombinant human follicle-stimulating hormone (r-hFSH) approved for the treatment female infertility and a rare form of male infertility. Merck announced ...

Gonal-f ® RFF Redi-ject™ (follitropin alfa injection) is indicated for: Induction of ovulation and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to ...

DARMSTADT, Germany — The Food and Drug Administration has approved a pre-filled injector pen made by EMD Serono for infertile women, the company said Friday. The drug maker — the U.S. subsidiary of ...

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and ...

EMD Serono, the U.S. healthcare business of Germany's Merck KGaA (OTCPK:MKGAF), has brokered an agreement with the Trump administration to provide its in vitro fertilization at a deep discount to US ...

GENEVA, July 4, 2011 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the European Commission (EC) has granted an approval for three pre-filled, ...

The U.S. Food and Drug Administration has approved trospium chloride for the treatment of overactive bladder, a new device that delivers follitropin alpha for infertility, a new indication for ...